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PCardiac Imaging
Noninvasive Detection of Fibrosis Applying
Contrast-Enhanced Cardiac Magnetic Resonance
in Different Forms of Left Ventricular Hypertrophy
Relation to Remodeling
Andre Rudolph, MD, Hassan Abdel-Aty, MD, Steffen Bohl, MD, Philipp Boyé, MD,
Anja Zagrosek, MD, Rainer Dietz, MD, Jeanette Schulz-Menger, MD
Berlin, Germany
Objectives We aimed to evaluate the incidence and patterns of late gadolinium enhancement (LGE) in different forms of
left ventricular hypertrophy (LVH) and to determine their relation to severity of left ventricular (LV) remodeling.
Background Left ventricular hypertrophy is an independent predictor of cardiac mortality. The relationship between LVH and
myocardial fibrosis as defined by LGE cardiovascular magnetic resonance (CMR) is not well understood.
Methods A total of 440 patients with aortic stenosis (AS), arterial hypertension (AH), or hypertrophic cardiomyopathy (HCM)
fulfilling echo criteria of LVH underwent CMR with assessment of LV size, weight, function, and LGE. Patients with
increased left ventricular mass index (LVMI) resulting in global LVH in CMR were included in the study.
Results Criteria were fulfilled by 83 patients (56 men, age 57  14 years; AS, n  21; AH, n  26; HCM, n  36). Late
gadolinium enhancement was present in all forms of LVH (AS: 62%, AH: 50%; HCM: 72%, p  NS) and was cor-
related with LVMI (r  0.237, p  0.045). There was no significant relationship between morphological obstruc-
tion and LGE. The AS subjects with LGE showed higher LV end-diastolic volumes than those without (1.0  0.2
ml/cm vs. 0.8  0.2 ml/cm, p  0.015). Typical patterns of LGE were observed in HCM but not in AS and AH.
Conclusions Fibrosis as detected by CMR is a frequent feature of LVH, regardless of its cause, and depends on the severity of
LV remodeling. As LGE emerges as a useful tool for risk stratification also in nonischemic heart diseases, our
findings have the potential to individualize treatment strategies. (J Am Coll Cardiol 2009;53:284–91) © 2009
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.08.064e
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teft ventricular hypertrophy (LVH) is an independent
redictor of cardiac mortality, regardless of its etiology
1–4). Left ventricular hypertrophy can be caused by 2 main
athophysiologically distinct categories, namely primary or
econdary LVH. In hypertrophic cardiomyopathy (HCM)
he LVH is mainly genetically determined (5), in contrast to
ortic stenosis (AS) and arterial hypertension (AH), where
VH is a compensatory mechanism to pressure overload (6).
See page 292
Histopathologic studies have shown myocardial fibrosis
n HCM, AS, and AH (7–10), and myocardial fibrosis itself
s associated with increased risk of cardiac sudden death and
ongestive heart failure (9,11–13). Novel therapeutic strat-
rom the Franz-Volhard-Klinik, Charite Campus Buch, HELIOS-Kliniken Berlin,
niversitätsmedizin Berlin, Berlin, Germany.t
Manuscript received May 5, 2008; revised manuscript received July 24, 2008,
ccepted August 12, 2008.gies are expected to target fibrosis by inhibition of humoral
athways (e.g., the renin-angiotensin-aldosterone system)
14). Cardiovascular magnetic resonance (CMR) offers the
nique opportunity to noninvasively quantify both LVH
ith high reproducibility (15) as well as myocardial fibrosis
as defined by late gadolinium enhancement [LGE]) (16)
ith high spatial resolution (17) and thus might provide a
seful tool with which to monitor novel therapeutic strate-
ies targeting these phenomena. Data relating the pattern
nd degree of fibrosis to secondary LVH are lacking, and
here are no studies addressing this in LVH due to AH.
ccordingly, we aimed to evaluate the incidence and pat-
erns of LGE in different forms of LVH and to determine
ts relation to severity of left ventricular (LV) remodeling.
ethods
etting. Four hundred forty inpatients and outpatients
ith LVH (M-mode–based measurements of LV-wall
hicknesses referenced to height and corrected for sex) due
o AS, AH, or HCM were screened (18). All patients
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January 20, 2009:284–91 Late Enhancement in LVHnderwent a comprehensive CMR examination, and LV
ass, end-diastolic volume, ejection fraction (EF), and the
mount of LGE were quantified.
nclusion criteria. We used the following inclusion cri-
eria: LVH defined from CMR as a left ventricular mass
ndex (LVMI) 1.06 g/cm in men and 0.8 g/cm in
omen (19). Normal values were obtained from a sample
f healthy volunteers (n  147, age 19 to 74 years).
xclusion criteria. Subjects with evidence of coronary
rtery disease by coronary angiography (n  64) or clinical
ssessment were excluded. Young patients (age 40 years)
ith a low pre-test probability lacking the usual risk factors
diabetes, smoking, AH, hyperlipidemia, family history of
oronary artery disease) were included without invasive
oronary angiography. Also excluded were patients with
evere arrhythmia or general contraindications for CMR.
Ethical approval was obtained from the local Research
thics Committee. All subjects provided written informed
onsent.
efinitions. Aortic stenosis was established in echocar-
iography by measurement of aortic valve pressure gra-
ient and was confirmed by CMR-derived planimetry of
ortic valve area (20). In accordance with American
ollege of Cardiology guidelines, AS was graded as
ollows: mild: 1.5 cm2; moderate: 1.5 to 1.0 cm2; and
evere: 1.0 cm2 (21).
Patients were assigned to AH if blood pressure was above
39 mm Hg systolic or 89 mm Hg diastolic in multiple
easurements, as recommended in European Society of
ardiology guidelines 2007 (22).
Diagnosis of HCM was established by clinical criteria,
ncluding echocardiography, according to the current guide-
ines (23). In this study, only patients with global LVH
increased LVMI) were included. Obstruction was verified by
MR and defined as an LV outflow tract area2.7 cm2 (24).
mage acquisition. CMR was performed on 3 1.5-T
ardiac-dedicated clinical magnetic resonance systems (So-
ata/Avanto, Siemens Medical Solutions, Erlangen, Ger-
any, and CV/i, General Electric Health Care, Waukesha,
isconsin). The CMR protocol consisted of a functional
tudy, additional specific studies (planimetry of aortic valve
rea in AS, planimetry of LV outflow tract area in HCM),
nd LGE imaging.
For the functional studies, 3 standard long-axis slices and a
tack of contiguous short-axis slices (slice thickness: 10 mm,
o gap, 30 phases/RR-interval) were acquired with
lectrocardiography-gated steady-state free-precession cine-
mages (Sonata: repetition time 2.9 ms, echo time 1.2 ms, flip
ngle 80°, matrix 256  146, field of view typically 340 mm,
andwidth 930 Hz/pixel; CV/i: repetition time 3.8 ms, echo time
.6 ms, flip angle 45°, matrix 256  192) in breath-hold
echnique. In HCM, the LV outflow tract area was quantified as
escribed recently (24). Planimetry of aortic valve area was per-
ormed as established by Friedrich et al. (25,26). The LGE images
overing the LV were acquired 10 min after intravenous injection
f 0.2 mmol gadolinium-diethyltriaminepentaacetic acid (Mag- gevist, Bayer Schering Pharma,
ermany) with a segmented in-
ersion recovery sequence with an
nversion time optimized to null
ormal myocardial signal (TI be-
ween 200 ms and 300 ms). The
GE images were acquired in
ame position as the functional
tudies and in end-systole. Ques-
ionable LGE was considered only
f it could be reproduced in a sec-
nd plane perpendicular to the
nding or by changing the read-
ut direction.
mage analysis. For quantifica-
ion of LV function and volumes,
he endocardial and epicardial
ontours were manually drawn in
nd-systole and -diastole with
edicated software (MASS 6,
edis, Leiden, the Nether-
ands). The LV mass was calcu-
ated from the total myocardial
olume multiplied by the specific gravity of the myocardium
1.05 g/ml). The LV mass and LV end-diastolic volume
ere indexed to height in cm.
Late gadolinium enhancement was defined as myocardial
reas with signal intensity above the average of apparently
ormal myocardium plus 2 standard deviations. Areas of
GE were manually traced, and total mass of LGE was
alculated and expressed as percentage LGE. The distribu-
ion and pattern of LGE was visually analyzed in a 17-
egment model (27).
tatistical analysis. Statistical analyses were performed
ith SPSS version 13.0 for windows (SPSS Inc., Chicago,
llinois). Data are presented as mean  SD. Continuous
ariables were compared with the unpaired t test. Noncon-
inuous variables were compared with the chi-square test.
e tested for data normality with the Kolmogorov-
mirnov test. Group comparisons were performed with
nalysis of variance with Bonferroni post hoc test for
ormally distributed data and the Kruskal-Wallis H test
hen data were not normally distributed. All correlations
ere performed with the Spearman correlation coefficient.
ifferences were considered significant when p  0.05.
esults
tudy population. Of the 440 screened patients, 83 (56
en, age 57  14 years) fulfilled our inclusion criteria. A
arge proportion of the screened patients were excluded due
o the lack of global LVH (as defined by increased LVMI in
MR). All CMR images were of diagnostic quality.
In the entire study population the LVMI was 1.34 0.37
Abbreviations
and Acronyms
AH  arterial hypertension
AS  aortic stenosis
CMR  cardiovascular
magnetic resonance
EF  ejection fraction
HCM  hypertrophic
cardiomyopathy
LGE  late gadolinium
enhancement
LV  left
ventricle/ventricular
LVEDVI  left ventricular
end-diastolic volume index
LVH  left ventricular
hypertrophy
LVMI  left ventricular
mass index
RV  right
ventricle/ventricular/cm (men: 1.43  0.36 g/cm, women: 1.15  0.31 g/cm,
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Late Enhancement in LVH January 20, 2009:284–91 0.001). The left ventricular end-diastolic volume index
LVEDVI) was 0.95  0.26 ml/cm (men: 1.00  0.26
l/cm, women: 0.84  0.22 ml/cm, p  0.003). There was
o difference in LVMI and LVEDVI between groups. The
F was within normal range (mean: 69  12%, men: 67 
2%, women: 73  10%, p  0.025), but significant
ifferences (p  0.05) between AH and HCM or AS were
oted (Table 1).
GE in entire population. The incidence of LGE was
3% (men: 66%, women: 56%, p  NS) for the entire
opulation and was the highest in HCM but was not
ignificantly different among the subgroups. This remained the
ase when AS and AH were combined together as “secondary”
VH and compared with HCM as primary LVH.
The amount of LGE was 19  22 g (men: 20  25 g,
omen: 17  13 g, p  NS). The percentage LGE was
ignificantly higher in HCM than in the other groups (p 
.05). The LVMI correlated significantly to the amount of
GE (r  0.237, p  0.045) (Fig. 1) in the entire
opulation and HCM but not in AS or AH. In general,
atients with positive LGE had higher LVMI and higher
aximum end-diastolic wall thickness than patients with
egative LGE (Fig. 2). The LVEDVI and EF did not
orrelate to LGE.
GE in AS. The LGE in AS (n 21) was present in 62%
n 13). Generally the lesions were small and focal with an
verage amount of 8  8 g (3  3% of the total LV mass).
he degree of stenosis was not related to the presence of
GE. The incidence of LGE in severe AS (n 11) was not
ignificantly different from intermediate or mild AS (55%
s. 70%, p 0.466). Aortic stenosis with LGE had a higher
VMI (1.4 0.2 g/cm vs. 1.1 0.3 g/cm, p 0.028) (Fig.
) and a higher LVEDVI (1.0  0.2 ml/cm vs. 0.8  0.2
l/cm, p  0.015) compared with AS without LGE. The
mount of LGE was not significantly correlated with LVMI
r 0.261, p 0.194) (Fig. 1). No specific pattern of LGE
ould be identified, but lesions were usually non-
ubendocardial. The cumulative segmental involvement
or each segment is shown in Figure 3. There was no
omparison of Patient Groups
Table 1 Comparison of Patient Groups
AS
(n  21)
AH
(n  26)
HCM
(n  36)
Intergroup
Differences
(p Value)
AVA (cm2) 1.0 0.3 — —
LVOT obstruction (n) — — 19
EF (%) 70 9 59 10* 75 9 0.001
LVMI (g/cm) 1.3 0.3 1.3 0.3 1.4 0.4 0.490
LVEDVI (ml/cm) 0.9 0.2 1.0 0.3 0.9 0.2 0.206
LGE (%) 62 50 72 0.203
%LGE 3 3 5 4 12 9† 0.001
Ejection fraction (EF) was significantly lower in arterial hypertension (AH) compared with the other
groups (p  0.01). †Amount of fibrosis was significantly higher in hypertrophic cardiomyopathy
HCM) compared with the other 2 groups (p  0.01).
AS  aortic stenosis; AVA  aortic valve area; LGE  late gadolinium enhancement; LVEDVI 
eft ventricular end-diastolic volume index; LVMI  left ventricular mass index; LVOT  lefta
entricular outflow tract; %LGE  total mass of late gadolinium enhancement calculated and
xpressed as percentage late gadolinium enhancement.ignificant relationship between the presence of LGE and
F (Table 2).
GE in AH. All patients in this group (n  26) had
rimary AH and were under routine medical treatment
beta-blockers: 70%, angiotensin-converting enzyme inhib-
tors: 50%, angiotensin II receptor type 1 blockers: 15%,
alcium channel blockers: 40%, diuretics: 50%, aldosterone
ntagonists: 0%). There was no significant influence of
edication on LVMI or LGE.
Late gadolinium enhancement was present in 50% of
he patients (n  13). In the subgroup with LGE the
mount of LGE was 11  9 g (5  4% of the total LV
ass). There was no significant relationship between
VMI, LVEDVI, or EF and presence of fibrosis (Fig. 2,
able 2). However, we observed a trend toward higher
VMI in the LGE positive patients (Fig. 2). There were
o age differences between subgroups with and without
GE. No specific pattern of LGE could be identified, but
esions were predominantly nonsubendocardial (95%).
he cumulative segmental involvement is shown in
igure 3.
GE in HCM (n  36). In 72% of the patients (n  26)
GE could be detected. In the subgroup with LGE the
mount of LGE was 30  26 g (12  9% of the total LV
ass). Obstruction in HCM was not related to presence of
GE (LGE in hypertrophic obstructive cardiomyopathy:
9%, LGE in hypertrophic nonobstructive cardiomyopathy:
5%, p  0.341). The presence of LGE was associated with
igher LVMI (1.5  0.5 g/cm in HCM with LGE vs. 1.2 
.2 g/cm in HCM without LGE, p  0.018) (Fig. 2). The
mount of LGE was significantly correlated with LVMI
r  0.354, p  0.038) (Fig. 1) and the maximum end
iastolic wall thickness (r  0.441, p  0.012). There
as no relationship between LGE and LVEDVI (Table
). The LGE in HCM was predominantly located in the
nteroseptal and inferoseptal segments, at the insertion
oints of the right ventricle (RV) and was typically
on-subendocardial. The cumulative segmental involve-
ent is presented in Figure 3. Eighty-four percent of the
atients with positive LGE had their lesion in the
egment of maximum wall thickness. There was no
ignificant relationship between the presence of LGE and
F (Table 2).
iscussion
lthough LVH is a well-established independent risk factor
or cardiac mortality, only very few studies have attempted
o explore the underlying myocardial tissue alterations,
articularly with respect to fibrosis. This is reflected in part
y the lack of noninvasive imaging modalities with the
bility to simultaneously assess both LVH and scarring.
herefore, we designed our study to assess the capability of
MR to study fibrosis over the wide spectrum of LVH
omprising both the primary, genetically determined HCM
s well as the secondary adaptive pattern of LVH.
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January 20, 2009:284–91 Late Enhancement in LVHGE in secondary LVH. Late gadolinium enhancement
eems to be a frequent finding in adaptive LVH due to
ressure overload. This is probably due to focal scarring
aused by ischemic necrosis. According to the “ischemic
ore” hypothesis, irreversible myocardial injury occurs sec-
ndary to a mismatch between LVH and blood supply,
esulting in myocardial ischemia (28). Additionally, LVH is
ssociated with relative reduction of capillary density, be-
ause capillary angiogenesis does not occur in parallel with
ypertrophying myocytes (29). These notions are supported
y earlier studies observing myocyte degeneration and re-
lacement fibrosis in response to pressure overload (30).
xperience with LGE in secondary LVH is limited to a
Figure 1 Relation Between LGE and LV Mass
Correlation between left ventricular mass index (LVMI) and the amount of late gad
in the entire LGE() population as well as the different subgroups of left ventriculaingle study in which Debl et al. (31) assessed LGE in AS snd compared it with findings in HCM. Our findings
xtend those of Debl et al. (31) to the novel setting of
ypertension-related LVH. Interestingly, however, we
ould not reproduce the tight relationship between pressure
verload and LVH and the presence of LGE in AS that
hey observed. The main difference between both popula-
ions was the better EF in the AS patients in the present
tudy, and this might partially explain this discrepancy.
ur findings thus underline that the state of affairs
mong pressure overload, LVH, and focal fibrosis is
omplex and seems to extend beyond a simple causality.
n AS the LV mass predicts the development of heart
ailure independent of the severity of AS (32). Our data
enhancement (LGE)
hypertrophy in both sexes (red  women, blue  men).olinium
r (LV)how the tight relationship between LV mass and myo-
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Late Enhancement in LVH January 20, 2009:284–91ardial fibrosis, and it seems conceivable that fibrosis is
he underlying cause for a worse clinical outcome in AS
ith increased LV mass.
In our AH cohort the systolic LV function was preserved
nd unrelated to the presence of LGE. There is a known
elationship between myocardial fibrosis and diastolic heart
ailure (33). Diastolic heart failure is a common feature in
ypertensive heart disease and is caused by abnormalities in
yocardial relaxation and ventricular compliance. Approx-
mately 50% of patients hospitalized for heart failure have
reserved systolic function. Although the in-hospital mor-
ality risk is lower in these patients, the duration of
ospitalization is similar to that of heart failure patients
ith systolic dysfunction (34). The PIUMA (Progetto
pertensione Umbria Monitoraggio Ambulatoriale) Trial
as shown a prognostic impact of diastolic heart failure
egarding cardiovascular events (35). Contrast-enhanced
MR might help to determine the individual risk of
iastolic heart failure and might impact upon therapeutic
ecision-making.
GE in primary LVH. In agreement with previous stud-
es, we observed LGE in approximately 70% of HCM
atients. We and others have observed a tight correlation
etween LVH and fibrosis (31,36). The exact pathophysi-
logical grounds of LGE in HCM are not clear, but focal
brosis, particularly collagen, seems to play a major role.
oon et al. (37) and Papavassiliu et al. (38) showed a strong
orrelation between LGE and increased collagen in 2
istologic case reports. The lack of correlation between
brosis and obstruction is interesting in many aspects. First,
t supports the hypothesis that fibrosis in HCM is geneti-
Figure 2 LV Mass in Patients With and Without LGE
Box plots showing the relation between LVMI and LGE. The LGE positive patients hally determined rather than being a response to obstruction cn HCM. Indeed, Moon et al. (36) suggested a close link
etween LGE and certain troponin mutations in HCM.
econd, because fibrosis is independent of obstruction, one
ight speculate that identifying focal fibrosis by CMR
ould provide additional complementary risk stratification
eans in HCM. Data from Moon et al. (36) seem to support
his premise, although prospective data are not yet reported.
he lack of dependency of LGE on pressure overload is
upported by the fact that fibrosis is a common histopatholog-
cal finding in apical HCM (39) and the weak relationship
etween severity of obstruction and outcome (40,41).
There are some possible explanations for focal fibrosis in
CM. Maron et al. (42) found, particularly in the septum,
umen loss and wall-thickening of the intramural coronary
rteries. Recent studies described microvascular dysfunction
ith hypoperfusion particularly in regions with severe hyper-
rophy (43,44). Ischemia results from microvascular disease,
nd increased end diastolic pressure together with the increased
emand of LVH might initiate the processes of ischemic
carring. It remains unclear why we and other investigators
bserved a typical pattern of LGE with frequent involvement
f the septum, particularly the RV insertion points (45). It
ould be that wall stress is particularly high at the insertion
oints or that LGE in these locations represents plexiform
brosis containing the crossing-fibers of LV and RV (46–48)
r crossing-fibers within the LV (49).
linical implications. The identification of fibrosis in
rimary and secondary LVH has several potential clinical
mplications. The emerging link between LGE-identified
brosis and ventricular arrhythmia in HCM (50) indi-
her LVMI. Abbreviations as in Figure 1ad higates that this approach might provide novel additional
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January 20, 2009:284–91 Late Enhancement in LVHisk stratification measures supplementary to the tradi-
ional risk factors.
An association among hypertensive blood pressure
egulation, LVH, cardiac fibrosis, and the development
f heart failure is commonly accepted (51). The renin-
ngiotensin-aldosterone system seems to play an impor-
ant role in the pathways of adverse remodeling, includ-
ng LVH and fibrosis (52). Magnetic resonance imaging
ight offer a unique opportunity to simultaneously mon-
tor the fibrosis-reducing and anti-remodeling effects of
ovel treatment strategies. However, we did not find a
elation between medical therapy and either the presence
f LGE or the LV mass.
The classical definition of HCM necessitated the absence
f other disorders that could explain LVH (23). It is,
Figure 3 Incidence and Patterns of LGE
(Left) Incidence of late gadolinium enhancement (LGE) in patients with aortic sten
Incidence of LGE within each segment (percentage) of all patients, including those
and inferoseptal. In AS and AH no specific pattern of fibrosis could be identified. (owever, increasingly recognized that HCM, especially in plderly patients (53), might coexist with other disorders such
s hypertension that might also result in LVH. On the basis
f the results of this study, one can cautiously speculate that
he pattern of fibrosis in HCM with predilection to involve
he RV insertion points could provide a means with which
o elucidate the underlying cause of LVH (46).
Recent reports showed that the presence and amount of
GE is associated with worse outcome in ischemic heart
isease (54) and in both dilated and HCM (55,56). In the
resent study we showed that LGE is a frequent finding in
ifferent forms of LVH. Therefore, LGE might be a
aluable tool for better risk stratification in these patients.
echnical considerations and limitations. A small frac-
ion of our patients did not undergo coronary angiography
o exclude coronary artery disease. However, their clinical
S), arterial hypertension (AH), and hypertrophic cardiomyopathy (HCM). (Middle)
nd without LGE. In HCM the late enhancement was predominantly anteroseptal
Representative short-axis slice images showing location of LGE (red arrows).osis (A
with a
Right)rofile rendered coronary artery disease unlikely. Moreover,
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Late Enhancement in LVH January 20, 2009:284–91one of these patients exhibited an infarct-typical pattern of
GE with subendocardial enhancement, as would be ex-
ected on the basis of the wave-front concept characteristic
f coronary artery disease (57). The limited sample size in
he LVH subgroups we studied did not allow us to explore
everal other factors (e.g., medications and sex) that could
heoretically affect LGE in LVH. This likely resulted from
he strict inclusion criteria we used to define LVH. Future
tudies with larger patient populations are definitely
arranted.
onclusions
ibrosis as detected by CMR is a frequent feature of LVH
egardless of its cause and depends on the severity of LV
emodeling. As LGE emerges as a useful tool for risk-
tratification also in nonischemic heart diseases, our findings
ave the potential to influence therapeutic strategies and to
mplify the characterization of disease progress by nonin-
asive imaging.
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